Jazz Pharmaceuticals JAZZ Share-Based Payment Arrangement, Expense, after Tax
Share-Based Payment Arrangement, Expense, after Tax at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's share-based payment arrangement, expense, after tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's share-based payment arrangement, expense, after tax?
- Jazz Pharmaceuticals (JAZZ) reported share-based payment arrangement, expense, after tax of $44.7M in Q1 2026.
- How has Jazz Pharmaceuticals's share-based payment arrangement, expense, after tax changed year-over-year?
- Jazz Pharmaceuticals's share-based payment arrangement, expense, after tax decreased by 23.1% year-over-year, from $58.1M to $44.7M.
- What is the long-term trend for Jazz Pharmaceuticals's share-based payment arrangement, expense, after tax?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's share-based payment arrangement, expense, after tax has grown at a 11.4% compound annual growth rate (CAGR), from $155.21M to $239.3M.
- What does share-based payment arrangement, expense, after tax mean?
- The after-tax cost of providing stock-based compensation to employees.
- How do you interpret share-based payment arrangement, expense, after tax?
- An increase suggests higher non-cash compensation costs, which may dilute existing shareholders or reflect aggressive talent retention strategies.
- How does share-based payment arrangement, expense, after tax compare across companies?
- Standard across all public companies; typically analyzed as a percentage of total operating expenses.